Trials / Completed
CompletedNCT03345082
A Dose Ranging Study of OPT-302 With Ranibizumab in Neovascular (Wet) AMD
A Dose-Ranging Study of Intravitreal OPT-302 in Combination With Ranibizumab, Compared With Ranibizumab Alone, in Participants With Neovascular Age-Related Macular Degeneration (Wet AMD)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 366 (actual)
- Sponsor
- Opthea Limited · Industry
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Not accepted
Summary
A multicentre, randomised, parallel group, sham-controlled, double-masked, dose-ranging study, investigating two doses of OPT-302 in combination with ranibizumab compared with ranibizumab with sham, over six consecutive monthly dosing cycles in participants with neovascular (wet) AMD.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | OPT-302 | Intravitreal injection |
| BIOLOGICAL | ranibizumab | Intravitreal injection |
| OTHER | sham intravitreal injection | Sham (mock) intravitreal injection |
Timeline
- Start date
- 2017-11-06
- Primary completion
- 2019-05-14
- Completion
- 2019-05-14
- First posted
- 2017-11-17
- Last updated
- 2021-01-12
Locations
108 sites across 10 countries: United States, Czechia, France, Hungary, Israel, Italy, Latvia, Poland, Spain, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03345082. Inclusion in this directory is not an endorsement.